Search clinical trials for: anti-PD-1 or anti-PD-L1

Total 6955 results

Fudan University

Recruiting

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

Pancreatic Cancer

China
Beijing Friendship Hospital

Recruiting

Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma

Esophageal Carcinoma | Neoadjuvant Immunotherapy

China
Beijing Friendship Hospital

Recruiting

Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer

Colorectal Neoplasms

China
Fujian Cancer Hospital
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (REVO)

Esophageal Neoplasms | Esophageal Squamous Cell Carcinoma

China
Bio-Thera Solutions

Recruiting

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Endometrial Cancer

China
The First Affiliated Hospital of Soochow University

Recruiting

Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy (SEHC)

EBV Infection

China
Seoul National University Hospital

Completed

Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily

Parkinson Disease

Korea, Republic of
Peking University

Recruiting

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Liver Metastasis Colon Cancer | MSS | ctDNA Genotype | Failed From Standard Treatment

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Peking University
CARsgen Therapeutics Co., Ltd.

Completed

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Advanced Solid Tumor

China
Sun Yat-sen University

Active, not recruiting

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

DMMR Colorectal Cancer | MSI-H Colorectal Cancer | Locally Advanced Colorectal Cancer

China
Sichuan University
Chengdu MedGenCell, Co., Ltd.

Completed

PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer

Metastatic Non-small Cell Lung Cancer

China
Pfizer

Completed

A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)

Healthy

United States
Celldex Therapeutics

Terminated

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Melanoma

United States
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Sun Yat-sen University

Recruiting

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Colorectal Cancer | Liver Metastases

China
Bio-Thera Solutions
Wuhan Union Hospital, China

Active, not recruiting

Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects

Healthy Male Subjects

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Renal Cell Carcinoma | Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Solid Tumors

China
Chen Xiaoping

Completed

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

Recurrence | HCC

China
Sun Yat-sen University
Guangzhou No.12 People's Hospital; Kaiping Central Hospital

Withdrawn

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Hepatocellular Carcinoma

China
Chuangzhen Chen

Recruiting

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors (ILDRV1)

Radiotherapy | Immune Checkpoint Blockade | Metastatic Extracranial Malignant Solid Neoplasm | Resistance to Immunotherapy

China
The Methodist Hospital Research Institute
Pfizer

Recruiting

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD-VACCINE)

Urothelial Carcinoma Bladder

United States
Peking Union Medical College Hospital

Recruiting

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Regorafenib

China
Zhejiang Cancer Hospital

Not yet recruiting

A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma

Chemotherapy Effect | Gray Zone Lymphoma | Relapse/Recurrence
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.; Shanghai Junshi Bioscience Co., Ltd.

Recruiting

PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC (Escape)

Esophageal Squamous Cell Carcinoma Abdominal Stage 0

China
Fudan University

Recruiting

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Gastric Cancer

China
GB006, Inc., a wholly owned subsidiary of Gossamer...
Merck Sharp & Dohme LLC

Terminated

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Renal Cell Carcinoma | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Castration-resistant Prostate Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Adenocarcinoma | Esophageal... and other conditions

United States, United Kingdom
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Esophageal Small Cell Carcinoma

China
University of Michigan Rogel Cancer Center
Medical College of Wisconsin

Completed

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

Multiple Myeloma

United States
Dong Wang

Unknown

Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC

Non-squamous Non-small Cell Lung Cancer

China
Pfizer

Completed

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

Healthy

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; Stand Up To Cancer; Aduro Biotech, Inc.; American Association... and other collaborators

Completed

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

Previously Treated Metastatic Adenocarcinoma of the Pancreas

United States
Beijing Friendship Hospital
Xuanwu Hospital, Beijing; Beijing Chao Yang Hospital; Tianjin Medical University... and other collaborators

Recruiting

Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.

Colorectal Neoplasms

China
Aalborg University

Completed

Investigation of a New Human Model for Itch

Itch

Denmark
University of Pennsylvania
Parker Institute for Cancer Immunotherapy; Tmunity Therapeutics

Terminated

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Melanoma | Multiple Myeloma | Myxoid/Round Cell Liposarcoma | Synovial Sarcoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

Metastatic Pancreatic Adenocarcinoma

United States
Sun Yat-sen University

Recruiting

Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Triple Negative Breast Cancer

China
Amgen

Completed

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Belgium, Austria, Singapore, Australia, Netherlands, France, Japan, Taiwan, Canada
Aarhus University Hospital
Rigshospitalet, Denmark; Herlev Hospital

Recruiting

TDM for Optimized Outcome in Patients With mRCC.

Kidney Cancer | Renal Cell Carcinoma Metastatic | Drug Toxicity | Drug Side Effect | Drug Mechanism

Denmark
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Oligometastatic Disease | Immunotherapy | Esophagus Cancer | Chemoradiotherapy

China
Fudan University

Recruiting

FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)

Triple-negative Breast Cancer

China
St George's, University of London
Wingate Institute of Neurogastroenterology

Recruiting

Gastro-intestinal Physiology After Anti-Reflux Procedures (GASP)

Gastroesophageal Reflux

United Kingdom
Lei Li

Recruiting

Donafenib for Recurrent Cervical Cancer

Chemotherapy | Recurrent Cervical Carcinoma | Survival Outcomes | Targeted Therapy | Adverse Effect | Metastatic Cervical Carcinoma | Persistent Advanced Cervical Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

Non-Small Cell Lung Cancer

China
Yonsei University

Unknown

A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation

Coronary Artery Disease

Korea, Republic of
Goethe University

Active, not recruiting

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group (RADIANCE)

Anal Cancer | Anal Carcinoma | Anal Cancer Stage III | Anal Cancer Stage II

Germany, Switzerland, Austria
Pfizer

Completed

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

Venous Thrombosis

Australia, United States, Spain, Czech Republic, Portugal, Canada, South Africa, Italy, Colombia, Poland, France, Chile, Russian Federation, Denmark, United Kingdom, Slovakia
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors. (SkinHealth)

Melanoma | Kidney Cancer | Breast Cancer | Gastric Cancer | Lung Cancer | Bladder Cancer | Skin Cancer | Head Neck Cancer

Italy
Sun Yat-sen University
Akeso Pharmaceuticals, Inc.

Recruiting

Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer

China

Search clinical trials for: anti-PD-1 or anti-PD-L1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations